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Effects of T N F a  and verocytotoxin cytotoxicity in hum an glomerular 
m icrovascular endothelial cells. In the pathogenesis of the hemolytic 
uremic syndrome (HUS), endothelial damage of glomeruli and arterioles 
of the kidney appears to play a central role. Previous studies have shown 
that verocytotoxin-1 (VT-1) cytotoxicity on human vein endothelial cells 
require additional stimuli, in particular the inflammatory mediator tumor 
necrosis factor alpha (TN Fa). In this study the effects of VT on human 
glomerular microvascular endothelial cells (GM VEC) were examined. A 
reproducible method was developed for the isolation and purification of 
large numbers of highly purified GM VEC. The obtained G M V EC  were 
over 99% pure; their endothelial origin was demonstrated by the expres­
sion of the endothelial antigens von Willebrand factor, EN-4, PECAM-1 
and V,E-cadherin. U pon  stimulation with T N F a  the cells expressed the 
endothelial-specific adhesion molecule E-selectin. A  limited number of 
fenestra 1 structures was observed by scanning electron microscopy (SEM), 
suggesting glomerular origin of the endothelial cells. Cytotoxicity of VT-1 
to G M V E C  was evaluated by determ ination of the number of viable 
adherent cells and by assay of overall protein synthesis after exposure to 
varying concentrations of VT-1. In non-stimulated GMVEC, cytotoxicity 
of VT-1 was inversely related to the degree and duration of confluence, 
subconfluent cells being the most sensitive, In highly confluent GM VEC, 
VT cytotoxicity required pre-exposure of the cells to the inflammatory 
m ediator T N F a, which induced an increase in the number of V T  receptors 
on G M V EC . Thin layer chromatography of extracted glycolipids from the 
G M V E C  showed binding of VT-1 to globotriaosylceramide (Gb3), known 
to be the functional receptor for VT. There were no major differences in 
protein synthesis inhibition with equal concentrations VT-1 and VT-2. In 
conclusion, in this study we provide a reproducible method to isolate, 
purify and culture well characterized hum an G M V EC on a routine basis. 
In vitro studies with these G M V E C  demonstrate that VT cytotoxicity 
depends on the degree of confluence and the additional preexposure to 
the inflammatory m ediator T N F a. These observations provide further 
insight into the complex events that may occur in glomeruli in the 
pathogenesis of HUS.
The hemolytic uremic syndrome (HUS) is characterized by 
renal failure, thrombocytopenia and hemolytic anemia [1], Endo­
thelial damage of glomeruli and kidney arterioles appears to play 
a pivotal role in the pathogenesis of HUS. Histopathological 
studies of the kidney in HUS patients reveal swollen and detached
endothelial cells and deposits of fibrin, all within the glomerulus
[2]. In severe cases of HUS endothelial cell damage is not limited 
to the kidney, but extends to other organs, such as brain and 
pancreas. Infection with a verocytotoxin (VT) producing E, coli 
has been implicated in the etiology of the epidemic form of HUS
[3]. In vitro studies with umbilical vein and adult vein endothelial 
cells indicate that endothelial cells become move susceptible to 
VT  if prestimulated with inflammatory mediators [4-7]. Induction 
of the globotriaosylceramide (Gb3) receptor, known to be the 
functional receptor for VT, proved to be the mechanism by which 
inflammatory mediators induce increased susceptibility to V T  [6], 
A  number of observations have indicated morphological, bio­
chemical and functional heterogeneity between macro- and mi­
crovessel endothelial cells, and even between microvascular en­
dothelial cells derived from different organs [8]. Therefore, to test 
if non-stimulated glomerular microvascular endothelial cells 
(GMVEC) are more susceptible to verocytotoxin-1 (VT-1) than 
their venous counterparts, it would be desirable to directly study 
GMVEC. The isolation and culture of human renal [9] and 
glomerular [10-12] MVEC has been reported, but currently no 
procedure is available to culture human GMVEC on a routine 
basis. Here, we report on a reproducible method to isolate, purify 
and culture large numbers of GMVEC that are free of contami­
nating ceils, and on the characterization of these cells. Further­
more, we describe the effects of TNFa and the degree of 
confluence on VT cytotoxicity for human GMVEC. We found 
that VT-1 cytotoxicity for highly confluent GMVEC requires 
pre-exposure of the cells to the inflammatory mediator TNFa, 
which is similar to previous findings on umbilical and adult vein 
endothelial cells [4-7]. These data seem to contrast to observa­
tions by Obrig et al [13], who showed that VT-1 had an identical 
toxic effect on TNFa-stimulated and non-stimulated renal 
MVEC. To explain these apparent differences, we analyzed the 
effects of VT-1 on GMVEC during maintenance in a confluent 
culture, and demonstrate that the sensitivity of GMVEC for VT-1 
is markedly reduced in the post-confluent state.
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Methods
Isolai ion of glom eru li
Studies were performed with human kidneys not suitable for 
transplantation because of anatomical anomalies, technical or
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immunological reasons. Written consent was obtained from the 
Medical Ethical Review Board of the University Hospital Nijme­
gen, The Netherlands. In general, the procedure was started as 
soon as possible after explantation of the kidney, usually within 24 
to 72 hours. Glomeruli were isolated under sterile conditions by 
dissecting the cortex followed by a gradual sieving procedure 
(sieves with opening sizes 2000 ¡jlm to 53 jxm; Endecotts, London, 
UK). Depending on the age of the donor, the glomeruli were 
collected on top of the screens with opening sizes of 180,125,108, 
90 or 53 fjum and digested with 0,1% (wt/vol) collagenase type 2 
CLS (Worthington, NJ, USA) in M199 (Biowithaker, MD, USA) 
for two hours at 37°C. Following digestion glomerular remnants 
were shaken vigorously to loosen up the glomeruli and liberate the 
endothelial cells. Subsequently the glomerular remnants were 
washed, centrifuged and resuspended in complete media that 
consisted of M199 supplemented with 10% (vol/vol) newborn calf 
serum (NBCS; GIBCO, Grand Island, NY, USA), 10% (vol/vol) 
human serum (HS; local blood bank), 2 mmol/liter glutamine 
(ICN Biomedicals, Zoetermeer, The Netherlands), 100 IU/ml 
penicillin/0.1 mg/ml streptomycin and 5 U/ml heparin (Leo Phar­
maceuticals, Weesp, The Netherlands) and 150 mg/liter crude 
preparation of endothelial cell growth factor (prepared from 
bovine brains as described by Maciag et al [14]) and plated on 
gelatin (1%; Fluka BioChemika, Buchs, Switzerland) coated wells 
(Costar Corp., Cambridge, MA, USA).
Primary culture and purification
In general the glomerular remnants attached within one to two 
days, after which outgrowth of predominantly cells of epithelial 
and endothelial origin was noted. Daily monitoring of proliferat­
ing cells determined the exact timing of separating the endothelial 
and epithelial cells, usually within three to eight days after plating 
of the glomerular remnants. The purification procedure consisted 
basically of three steps. First, selective trypsinization was per­
formed, allowing endothelial cells to detach and leaving the 
epithelial cells attached to the plate. Selectivity in cell detachment 
was reached by incubating the cells with trypsin/EDTA (0.5 g 
trypsin '1:250/0.2 g EDTA in 1 liter of Modified Puck’s Saline A; 
Gibco) at room temperature for a short incubation period, the 
duration of which was determined during visual inspection of the 
cell layer by phase-contrast microscopy (about 60 seconds). Sec­
ond, to relieve glomerular remnants, which proved to be a source 
of contaminating cells when subcultured, trypsinized cells and 
glomerular remnants were filtrated through a 38 /xm sieve. The 
filtrate was collected, washed and pelleted by centrifugation 
(200 X g). Third, the pellet was resuspended in Hanks’ balanced 
salts (ICN Biomedicals)/10% (vol/vol) fetal calf serum (FCS; 
GIBCO) and incubated with a monoclonal antibody against 
PECAM-1 (CLB, Amsterdam, The Netherlands) for 30 minutes 
on ice. Excess of unbound anti-PECAM-1 monoclonal was re­
moved by washing for three times. Subsequently, an immunomag- 
netic separation technique with dynabeads coated goat anti­
mouse antibodies (Dynal A.S; Oslo, Norway) and a magnetic 
particle collector (Dynal A.S) was performed to selectively collect 
glomerular endothelial cells. In general the number of beads used 
was calculated according to the following formula: (total number 
of cells) X (% estimated endothelial cells) X 3. The use of too 
many beads per cell reduced the attachment of the endothelial 
cells. PECAM-1 positive cells were plated on gelatin-coated wells
and maintained at 37°C with 5% C02 atmosphere. The medium 
was changed every two to three days and cells were passaged with 
trypsin/EDTA onto gelatin-coated wells at a split ratio of 1:2 or 
1:3. In general it was necessary to repeat the immunomagnetic 
separation technique once or twice or to perform additional 
manual weeding to obtain pure cultures of GMVEC.
In case the epithelial cells seemed to overgrow the endothelial 
cells in the primary culture from morphological point of view, the 
protocol as described above was preceded by a negative immuno­
magnetic separation technique using an epithelial-cell specific 
antibody (CD 26; Pharmingen, San Diego, CA, USA) to remove 
the contaminating epithelial cells.
Characterization
Primary and serially passaged cultures were characterized using 
three criteria.
(1.) Mo?phological criteria. Outgrowth from collagenase treated 
glomerular remnants and subcultures were examined with a 
phase-contrast microscope. Photomicrographs were made at var­
ious passages using Technical Pan films.
(2.) Immunological criteria. The presence of endothelial cell- 
specific antigens was determined by performing indirect immuno­
fluorescence studies with a panel of endothelial cell-specific 
monoclonal antibodies (MoAb). GMVEC were seeded on gela­
tin-coated glass-coverslips and grown until confluence. Cells were 
fixed in 80% (vol/vol) aceton for 10 minutes at 4°C and rinsed with 
phosphate-buffered saline (PBS). The presence of von Willebrand 
factor was demonstrated by indirect immunofluorescence staining 
with rabbit anti-human von Willebrand antiserum [1:80 dilution in 
10% (vol/vol) pig serum; DAKO; Glostrup, Denmark] and FITC- 
swine anti-rabbit Ig (1:20 in PBS; DAKO). The presence of other 
endothelial-cell specific antigens such as PECAM-1, EN-4 antigen 
and V,E-cadherin was investigated by incubating the fixed cells 
with anti-PECAM-1 MoAb (10 x^g/ml; CLB, Amsterdam, The 
Netherlands), MoAb EN-4 [15] (10 yutg/ml; Sanbio, Uden, The 
Netherlands) and anti-V,E-cadherin MoAb [16] (1:500; provided 
by Dr. Dejana, Mario Negri Institute, Milan, Italy) in PBS/10% 
goat serum. After a 30-minute incubation period at room temper­
ature the cells were washed twice with PBS and incubated with 
FITC-goat anti-mouse Ig (1:20; DAKO). After a 30-minute 
incubation time at room temperature, cells were washed twice 
with PBS and mounted with Vectashield (Burlingame, CA, USA) 
under a coverslip and investigated using a fluorescence micro­
scope. Similar immunofluorescent assays were carried out using 
MoAb to control for contamination with mesangial-celis (anti-a- 
smooth muscle actin, clone 1A4; Sigma, Zwijndrecht, The Neth­
erlands) and epithelial cells (monoclonal anti-cytokeratin 8, M20; 
provided by Dr. G. van Muijen, University Hospital Nijmegen, 
The Netherlands [17]). The expression of the endothelial-cell 
specific adhesion molecule E-selectin upon stimulation with 
TNFa was determined by cell-ELISA, GMVEC were grown until 
confluence in 96-well tissue culture plastic plates (Costar Corp.) 
and subsequently exposed to TNFce (10 ng/ml) during a four-hour 
incubation period. Cells were rinsed once with M199 and fixed in 
0.025% glutaraldehyde. Following fixation wells were incubated 
with MoAb against E-selectin (ENA-2; gift of Dr. J. Leeuwen- 
berg, University Hospital Maastricht, The Netherlands [18]) 
diluted inM199/5%FCSata concentration of 10 /xg/ml during 60 
minutes at 37°C. The cells were washed twice with PBS/Tween
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and incubated with peroxidase labeled, goat anti-mouse second 
antibody (1:1000; DAKO) for 30 minutes at 37°C. After washes 
with PBS/Tween o-phenylenediamine-peroxide was added. The 
reaction was stopped by the addition of 2.5 mol/liter H2S04 (50 
¿¿1/well). Absorbency was read at 492 nm on a Titretek Multiscan. 
Absorbency with second antibody alone was subtracted from ail 
absorbency values expressed. Expression of E-selectin was also 
analyzed by performing immunofluorescence studies and FACS 
analysis as described above with minor adjustments, in that the 
cells were incubated with the primary and secondary antibodies 
diluted in PBS plus (PBS plus Mg2+ and Ca2+) and cells were only 
fixed after incubation with primary and secondary antibodies.
(3.) Ultrcistmcture. Evaluation of human GMVEC by scanning 
electron microscopy was performed by the osmium-thiocarbohy- 
drazide-osmium technique. GMVEC grown on gelatin coated 
glass-coverslips were rinsed with M199 and fixed for two hours at 
room temperature with 2.5% glutaraldehyde in 0.1 mol/liter 
cacodylate buffer. The cells were then rinsed carefully with 0.1 
mol/liter cacodylate/6.8% sucrose pH 7.38 and postiixed with 1% 
0 s04 in the same cacodylate buffer. Subsequently the cells were 
rinsed with aquabidest and immersed in 1% filtrated thiocarbo- 
hydrazide-solution (TCH). Following immersion, alternate fixa­
tion in OsO^ and immersion in TCH and fixation in 0s04 were 
repeated after which the cells were selectively dehydrated in 
graded alcohol solutions and critical point dried. Cells were 
visualized with a SEM Jeol 1200 EX/2 at an accelerating voltage 
of 50 KV.
Cytotoxicity assay
GMVEC were cultured in complete medium on gelatin coated 
24-well plates and grown until confluence. Five days after reaching 
confluence (highly confluent) cells were preincubated with or 
without TNFa (10 ng/ml) for 24 hours. The next day the medium 
was aspirated and new medium with different concentrations of 
VT-1 and VT-2 (provided by Prof Karmali; Hospital for Sick 
Children, Toronto, Canada) was added. VT-1 and VT-2 were 
diluted in medium with 20% FCS instead of 10% NBCS and 10% 
HS, since previous studies have indicated that NBCS and HS may 
have neutralizing activity against VT-1 and VT-2. After 8 and 24 
hours the cells were washed with PBS, released with trypsin/ 
EDTA and subsequently viable, Trypan blue excluding cells were 
counted with a hemocytometer. In order to study the influence of 
confluence, cells at different degrees of confluence were preincu­
bated with TNFa and tested for VT-1 cytotoxicity as described 
above.
Iodination o f VT-1 and the binding o f f251-VT-1 to human
GMVEC
VT-1 was radiolabeled with Na~125I according to the Iodogen 
procedure [19]. The radioactive activity of 125I-VT-1 ranged from 
'10 to 12 jtiCi/jug of protein. GMVEC were grown in 24-well plates 
until they reached confluence. After five days the cells were 
preincubated with or without inflammatory mediators for 24 
hours at 37°C. Subsequently the GMVEC were washed with M199 
medium/0.1% human serum albumin (HSA) and incubated for 
three hours with 0.25 to 32 nmol/liter 125I-VT-1 in M l99 medium/ 
0.1% HSA at 0°C. After three hours the incubation medium was 
aspirated and the cells were washed for five times in M199 
medium/0,1% HSA. Cell-associated 125I-VT-1 was determined by 
solubilizing the cells in 400 ¡A 1 mol/liter sodium hydroxide at
room temperature and counting radioactivity in a gamma- 
counter. Non-specific binding was assessed in parallel incubation 
by determining 125I-VT-1 binding in the presence of a 100-fold 
excess of unlabeled VT-1, Cellular specific binding was calculated 
by subtracting the non-specific binding from the cellular binding 
of 125I-VT-1 as determined in the absence of unlabeled VT-1. A ll 
determinations were done in duplicate. Data were analyzed using 
the method described by Scatchard [20]* To investigate whether 
Gb3 is also the functional receptor for V T  in GMVEC, TNFa- 
stimulated GMVEC were incubated with a MoAb against Gb3 
[21] (MoAb anti-CD77; clone #38-13; Biodesign International, 
Kennebunk, ME, USA) one hour before and during assaying the 
binding of 125I-VT-1.
Glycolipid extraction and thin layer chromatography (TLC)
Highly confluent GMVEC were cultured in six-well plates (20 
cm2) for 24 hours with and without TNFa (10 ng/ml). Subse­
quently the cells were washed with PBS and trypsinized, after 
which glycolipids were extracted and separated by methods earlier 
described by Lingwood et al [22]. Following thin layer chroma­
tography, the silica gel TLC plate was incubated with 50 ml, 1.5 
nmol/liter 1251-VT-1 in 1% BSA and 0.05% Tween-20 in PBS 
during four hours at 4°C. The plate was washed extensively with 
PBS supplemented with 1% BSA and 0.05% Tween-20, air dried 
and analyzed by a Fuji BAS 1000 phosphor-imager.
Protein synthesis
Protein synthesis was determined by assaying the incorporation 
of 35S-labeled methionine (0.25 fiCi/ml complete medium) in 
3 5 S-proteins during an 8 to 24 hours incubation period with 
different concentrations of VT-1 and VT-2. After incubation, the 
cells were washed and 35S-labeled cellular proteins were precipi­
tated by adding 10% trichloroacetic acid. Precipitated proteins 
were dissolved in 0.3 ml 0.3 mol/liter NaOH, 60 1.5 mol/liter 
HC1 was added and precipitated radioactivity was counted in a 
liquid scintillation counter.
Results
Isolation and pwification of human GMVEC
Incubation of pure populations of human glomeruli, which were 
isolated by a gradual sieving procedure with collagenase for two 
hours at 37°C followed by vigorously shaking, resulted in small 
clumps consisting of glomerular remnants. These remnants at­
tached to gelatin-coated plates within one to two days. Following 
attachment, outgrowth of primarily endothelial and epithelial cells 
was noted (Fig. 1A), the latter easily overgrowing the GMVEC. 
As judged by phase-contrast microscopy the outgrowing endothe­
lial cells demonstrated a slightly elongated morphology with a 
nucleus containing one or two nucleoli and a dark perinuclear 
cytoplasm area that was surrounded by a bright halo. Epithelial 
cells displayed the epithelial cell specific cobblestone pattern of 
densely packed polygonal cells. Besides the tendency of the 
contaminating epithelial cells to overgrow the endothelial cells, 
these cells seemed to inhibit the growth of endothelial cells, 
probably by producing growth inhibiting factor(s). Therefore, it 
was crucial to remove epithelial cells and purify the endothelial 
cell populations. The purification procedure consisted basically of 
three steps: selective detachment of most of the endothelial cells 
by trypsin-EDTA treatment; removal of glomerular remnants by
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Fig. 5. VT-1 cytotoxicity is related to the degree o f confluence o f human 
GMVEC .  Human GMVEC of one representative donor out of three were 
grown to confluence, trypsinized and seeded 1:6 onto gelatin coated 24 
wells plates. Forty-eight hours before the indicated time points after 
trypsinization (as indicated on the x-axis) GMVEC were preincubated 
with either control medium (same culture medium without addition; open 
symbols) or TNFa (10 ng/ml; closed symbols) for 24 hours. Subsequently 
the cells were washed and exposed to either control medium or VT-1 (1 
nmol/liter) for 24 hours, after which the number of viable adherent cells 
was counted with a hemocytometer. GMVEC indicated by A were 
categorized subconfluent (<50% confluent), by B “just reaching conflu­
ence” and by C “highly confluent” for respectively two, four and seven 
days. A. Effect of VT-1 on the viability of non-stimulated-(open symbols) 
and TNFa-treated GMVEC (closed symbols). Symbols are: (V, T) control 
cells; (O, • )  VT-1 treated cells, li. Effect of VT-1 on the number of viable 
adherent cells expressed as percentage of control (calculated by dividing 
the number of viable cells after VT-1 treatment by the number of viable 
adherent cells exposed to control medium X 100%). Symbols are: (□) 
unstimulated GMVEC; (■) TNFa-prestimulated GMVEC. Similar re­
sults were obtained in two other experiments with two different donors.
based on inhibition of protein synthesis, newly synthesized pro 
teins were determined by assaying the incorporation of 35S 
methionine into total cellular proteins. In agreement with cell
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Fig. 6. TNFa increases the specific binding o f 1 2 5 I-VT-1 to human GMVEC. 
A. Human GMVEC of one representative donor were grown to “just 
reaching confluence” and pre-treated with either control medium (□) or 
TNFa (10 ng/ml; ■) for 24 hours. Subsequently the cells were incubated 
with increasing concentrations of 125I-VT-1 (0.25 to 32 nmol/liter) for 
three hours at 4°C, after which specific binding of 125I-VT-1 to GMVEC 
was calculated as indicated in the Methods section. B. Scatchard plot 
analysis of 123I-VT-1 binding to human GMVEC preincubated with either 
control medium (O) or TNFa (10 ng/ml; • )  for 24 hours.
synthesis of highly confluent GMVEC over a 24-hour incubation 
period, whereas it inhibited protein synthesis in subconfluent and 
confluent cells (Fig. 8). When the highly confluent human GM­
VEC were preincubated with TNFa for 24 hours, the protein 
synthesis rate was inhibited similarly to subconfluent cells. Table 
1 summarizes the results of protein synthesis inhibition by VT-1 in 
GMVEC differing in degree of confluence (N =  3). TNFa alone 
did not decrease overall protein synthesis. 
When the effect of VT-1 and VT-2 on protein synthesis 
inhibition on TNFa-stimulated GMVEC of two different donors
viability data, VT-1 alone did not or only slightly affect protein were compared, VT-1 was slightly more potent in inhibiting
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Table 1. VT-1 inhibitory effect on overall protein synthesis is related to the degree of confluence of human GMVEC
Incorporation of 35S-methionine in proteins % o f control
Donor 1 Donor 2 Donor 3
Without
TN Fa
With
TN Fa
Without
TNFa
With
TN Fa
Without
TN Fa
With
T N Fa
Subconfluent 54 35 5 2 51 30
Confluent 73 28 10 8 69 32
Highly confluent (2 days) 87 24 39 25 71 46
Highly confluent (4 days) 92 33 71 33 82 48
Highly confluent (7 days) 87 36 88 40 87 37
Experimental design as described in the legend of Figure 8 . The data of three independent experiments are given. The incorporation of 
35S-methionine in proteins is expressed as % of control [35S-methionine incorporation in proteins of VT -1  ( 1  nmol/liter) treated cells divided by 
35S~methionine incorporation in proteins of control cells X 100%].
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VT concentration, nmol/liter
Fig. 9. Effect o f VT-1 and VT-2 on protein synthesis by “highly confluent 
human GMVEC. Human GM VEC were grown to confluence and main­
tained confluent for five days. Subsequently the cells were pre-treated 
without (open symbols) or with T N Fa (10 ng/ml; closed symbols). After 24 
hours of preincubation, the cclls were washed and incubated with different 
concentrations (0.1 pmol/liter to 1 nmol/liter) of VT-1 (O, • )  and VT-2 
(A, A) for 24 hours. Incorporation of 35S-methionine in proteins was 
determined as described in the Methods section. Data are expressed as the 
mean of two different experiments with two different donors (% of 
control).
endothelial cells or need the local exposure to inflammatory 
mediators to up-regulate Gb3 receptors and become suscep­
tible to the cytotoxic effect of VT, as seen in venous endothelial 
cells.
Since Striker et al [10] and Green et al [12] described their 
methods to isolate and purify human glomerular endothelial cells, 
very few reports deal with glomerular endothelial cells in vitro,
»
reflecting difficulties in the process of isolating and purifying large 
numbers of glomerular microvascular endothelial cells devoid of 
contaminating mesangial- and epithelial cells. In this report we 
have described an adapted procedure that is reproducible, rela­
tively simple to perform and yields high numbers of GMVEC. It 
appeared to be crucial to avoid any contamination early in the 
process of purification because a minute contamination of epithe­
lial or mesangial cells causes inhibition of GMVEC proliferation 
and rapid overgrowth of the contaminating cells. By several
standard techniques the cultured cells have been characterized as 
pure populations of glomerular microvascular endothelial cells. 
The combined presence of the endothelial specific markers von 
Willebrand factor, V,E cadherin and EN-4 antigen and PECAM-1 
(which is only encountered on endothelial cells, leukocytes and 
platelets), demonstrates the endothelial nature of our GMVEC. 
Upon inflammatory activation the endothelial cell specific leuko­
cyte adhesion molecule E-selectin was also expressed. This agrees 
well with observations in vivo [29-33] showing an induction of 
E-selectin in glomeruli during inflammation. The presence of 
fenestral structures suggests that one of the specific properties of 
the glomerular endothelium is preserved in culture. Suboptimal 
expression of fenestrae in these human GMVEC may be due to 
the fact that they are cultured under static conditions. The need 
for dynamic flow to induce the expression of fenestrae in cultured 
glomerular endothelial cells was suggested by Ott, Olson and 
Ballermann [34] who, in contrast to our findings, did not observe 
fenestrae in bovine glomerular endothelial cells cultured under 
static conditions, but were able to induce the expression of 
fenestrae by shear forces.
Several papers have reported that HUVEC cultured under 
basal conditions are resistant to the cytotoxic effect of VT-1 [4-7]. 
When prestimulated with inflammatory mediators HUVEC be­
come susceptible to the cytotoxic effect of VT-1 presumedly by an 
up-regulation of the receptors for VT on the cell-surface [6]. 
Recently Obrig et al [13] have demonstrated that cell viability and 
protein synthesis of unstimulated renal endothelial cells was 
affected by VT with no alteration in sensitivity for VT when 
pre-exposed to TNFa or LPS. Furthermore, Obrig et al described 
high basal levels of VT receptor in renal endothelial cells reaching 
concentrations approximately 50 times higher than in H U V EC 
These data suggest a higher relative sensitivity of renal endothelial 
cells versus HUVEC and a possible explanation for localized 
involvement of the kidney. In our study, cytotoxic and protein 
synthesis inhibitory effects of VT were found only on GMVEC 
that were subconfluent, just reaching confluence or pre-exposed 
to the inflammatory mediator TNFa, but not in the highly 
confluent GMVEC. Because Obrig et al have used cells one day 
after seeding in wells, it is likely that they studied the effect of VT 
on subconfluent or confluent renal endothelial cells.
Several papers have reported that subconfluent cells display a 
significant higher binding capacity of radiolabeled VT-1 and a 
higher susceptibility to the cytotoxic effect of VT than confluent 
cells [6, 35, 36]. Most probably this higher susceptibility of 
subconfluent and confluent cells is related to the cell-cycle
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dependent expression of Gb3 on the cell-surface compounded 
with increased Gb3 turnover [36]. Our observation that the degree 
of confluence of GMVEC affects susceptibility for VT corre­
sponds with these findings. Since the half life of endothelial cells 
in the normal mature human body is approximately a hundred to 
thousand days [37] and autoradiographic analysis in glomeruli of 
rats demonstrated a constant rate of cell renewal of about 1% 
[38], we believe that from pathophysiological point of view, data 
on highly confluent cells are most appropriate in the study of the 
pathogenetic mechanisms of HUS.
Infections with VT producing E . coli most commonly involve 
isolates producing either VT2 alone or VT-2 with VT1. The 
structural genes of the two toxins share 58% overall nucleotide 
and 56% projected amino acid sequence homologies [39]. The 
toxins show similar physical properties such as toxin binding to 
Gb3 and inhibition of protein synthesis by the same mechanism, 
however, differences in biological activity have been observed. In 
vitro studies comparing the cytotoxic effects of VT-1 versus VT-2 
on HUVEC [40], Vero [41], HeLa [41] and Daudi cells [42] 
demonstrated reduced susceptibility to VT2. While performing 
studies with VT1 and VT2 hybrid toxins [43] it was found that the 
modulation in VT susceptibility is due to differences in the B 
subunit. Furthermore, Head, Karmali and Lingwood’s study pro­
vided evidence for reduced binding affinity of VT2 for Gb3 when 
compared to VT1 [43]. This observation corresponds to our 
finding concerning the slightly reduced cytotoxicity of VT2 in 
GMVEC, but is in contrast with a recent study by Louise and 
Obrig [40] suggesting an increased susceptibility of renal endo­
thelial cells for VT2. In vivo studies in mice [44] have demon­
strated enhanced lethality of Shiga-like toxin-2 when compared to 
Shiga-like toxin-1 (toxins closely related to VT-2 and VT-1, 
respectively), suggesting that differences in properties other than 
direct target cell lysis are responsible for the observed heightened 
sensitivity of animals to VT-2.
Since in vitro data described in this report do not provide strong 
evidence for an intrinsic enhanced basal susceptibility of GMVEC 
to VT as a possible explanation for the preferential glomerular 
microvascular endothelial cell damage observed in HUS patients, 
the local availability of inflammatory mediators in glomeruli may 
contribute to local susceptibility for the cytotoxic effect of VT. A 
local role for inflammatory mediators was also suggested by Harel 
et al [45] reporting that Shiga-like toxin-1 injection into transgenic 
mice, bearing a chloramphenicol acetyl transferase (CAT) re­
porter gene coupled to a TNFa promoter, induced CAT activity 
(reflecting stimulation of the TNF promoter) in the kidney but not 
in other tissues. Monocytes and macrophages, known to produce 
and release inflammatory mediators may be the source of locally 
produced glomerular inflammatory mediators. Of interest are 
recent in vitro studies of Tesh, Ramegowda and Samuel [46] and 
Van Setten et al [47], which describe the interaction of VT with 
murine peritoneal macrophages and human monocytes, respec­
tively. Both cells upon VT binding do not display protein synthesis 
inhibition but synthesize and release inflammatory mediators, 
suggesting a key role for monocytes in the process of endothelial 
cell damage in HUS. In vivo data supporting involvement of 
inflammatory mediators in the pathogenesis of HUS are provided 
by several papers demonstrating elevated concentrations of in­
flammatory mediators in plasma and urine among HUS patients 
[48-51], Other possible local sources of cytokine production
inside the glomerular capillaries such as mesangial [52, 53] and 
epithelial [54] cells need further investigation. It remains to be 
clarified for what reason inflammatory mediators are predomi­
nantly produced inside the glomerular capillaries.
Although our in vitro data strongly suggest that local availability 
of inflammatory mediators is essential for VT to result in a 
cytotoxic response, these data should be interpreted with some 
reserve. Since mainly children are affected by infection with a VT 
producing E. coli, it remains to be investigated whether GMVEC 
isolated from kidneys of juvenile origin display an increased 
sensitivity towards VT cytotoxicity when compared to GMVEC 
isolated from kidneys of adult origin. Of interest is the observation 
of Lingwood [55] that FITC labeled VT binds to human renal 
sections of infant <  two years and not to the glomerulus of the 
adult. It should be noted, however, that Lingwood for the most 
part examined kidney sections of minimal lesion nephrotic syn­
drome patients, where locally released cytokines may induce the 
Gb3 receptor [56-58] resulting in the observed enhanced VT 
binding.
We conclude from this study with highly purified GMVEC, 
showing glomerular microvascular endothelial cell specific fea­
tures, that VT cytotoxicity depends on the degree of confluence 
and the additional pre-exposure to inflammatory mediators. The 
latter are presumedly locally produced by monocytes and not only 
up-regulate the receptor for VT, but also exert a variety of 
pro-inflammatory and coagulatory effects on the endothelium, 
resulting in a cascade of events of mutually influencing factors in 
the end leading to glomerular capillary damage, as observed in 
HUS patients.
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